Black Friday is Now! Don’t miss out on up to 60% OFF InvestingProCLAIM SALE

Verona Pharma CFO Mark Hahn sells shares worth $632,760

Published 26/10/2024, 01:00
VRNA
-

Mark W. Hahn, the Chief Financial Officer of Verona Pharma plc (NASDAQ:VRNA), recently executed significant stock sales as reported in a filing with the Securities and Exchange Commission. On October 24 and 25, Hahn sold a total of 144,560 ordinary shares, amounting to approximately $632,760. The shares were sold at prices ranging from $4.375 to $4.3772 per share. Following these transactions, Hahn retains ownership of 13,669,360 shares in the company. These sales were conducted under a Rule 10b5-1 plan, which was established earlier this year on March 6.

In other recent news, Verona Pharma has made significant strides with the FDA approval and launch of Ohtuvayre, a treatment for Chronic Obstructive Pulmonary Disease (COPD). Piper Sandler and Wells Fargo (NYSE:WFC) have maintained their Overweight ratings on Verona Pharma shares, with price targets of $36.00 and $50.00 respectively. The positive ratings follow the successful launch of Ohtuvayre, which has seen a substantial uptake among healthcare providers since its approval in June 2024.

Verona Pharma's Q2 2024 earnings report revealed a strong financial position, with cash reserves exceeding $400 million. The company has initiated patient shipments through specialty pharmacies, targeting approximately 14,500 healthcare providers in the U.S. Furthermore, Verona Pharma has partnered with The Ritedose Corporation for the development and manufacturing of Ohtuvayre, and with Nuance Pharma for a Phase 3 clinical trial in China.

These recent developments demonstrate Verona Pharma's ongoing commitment to advancing COPD treatment and expanding its market reach. The company anticipates the assignment of a unique J-code for Ohtuvayre in January 2025, which is expected to enhance the drug's market uptake. Analysts from H.C. Wainwright and Piper Sandler have maintained their positive ratings on Verona Pharma shares, citing the company's strong trajectory and the potential of Ohtuvayre.

InvestingPro Insights

While Mark W. Hahn's recent stock sales might raise eyebrows, it's essential to consider Verona Pharma's broader financial picture. According to InvestingPro data, the company's market capitalization stands at $2.8 billion, reflecting significant investor interest. This interest is further evidenced by the stock's strong performance, with a remarkable 183.58% price return over the past year and a 121.16% return in the last six months.

However, investors should note that Verona Pharma is not currently profitable. The company reported an adjusted operating income of -$128.87 million for the last twelve months as of Q2 2024. This aligns with an InvestingPro Tip indicating that analysts do not anticipate the company will be profitable this year.

Despite the lack of profitability, Verona Pharma's stock is trading near its 52-week high, with the current price at 95.06% of that peak. This suggests strong market optimism about the company's prospects, possibly related to its drug development pipeline.

For those seeking a more comprehensive analysis, InvestingPro offers 14 additional tips for Verona Pharma, providing deeper insights into the company's financial health and market position.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.